---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-080484"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2025-08-26T23:59:59+00:00"
generated_at: "2026-05-17T09:58:48.909257+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OS Therapies terminates $15M equity line; $4.2M raised, burn reduced

## Summary
- Terminated ELOC Purchase Agreement with Square Gate effective Aug 26, 2025; no outstanding borrowings or fees.
- Recent warrant exercise exchange provided $4.2M gross proceeds to fund operations into mid-2026.
- Projected monthly burn in H2 2025 significantly lower than H1 2025, completing Phase 2b and Phase 1b treatment phases.
- Company focusing capital on advancing OST-HER2 toward approval and analyzing OST-504 prostate cancer data.

## SEC filing metadata
- accession: 0001213900-25-080484
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2025-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390025080484/0001213900-25-080484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390025080484/ea0254579-8k_ostherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-080484
- JSON: https://secwatch.observer/filing/0001213900-25-080484.json
- Plain text: https://secwatch.observer/filing/0001213900-25-080484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.